ArticleEuropean journal of nuclear medicine and molecular imaging2023
Assessment of myocardial fibrosis in patients with systemic sclerosis using [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06568783 (Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74 (FAPI-74) PET/MRI Imaging
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics-Where We Are at and Where We Are Heading: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Mechanisms of fibrosis and novel antifibrotic therapies.EULAR rheumatology open · 2026Review
- Next-generation molecular imaging of cardiac fibrosis.The international journal of cardiovascular imaging · 2026Review
- Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells.Nature communications · 2026Article
- Primary myocardial involvement in systemic sclerosis: pathophysiology, clinical manifestations and advances in cardiac imaging.Rheumatology (Oxford, England) · 2026Review
- Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026Article
- Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement.Rheumatology (Oxford, England) · 2026Article
- Expanding horizons: radiolabeled FAPI in imaging of autoimmune diseases.Frontiers in immunology · 2026Review
- Recent advances in nuclear medicine and their role in inflammatory arthritis: focus on the emerging role of FAPI PET/CT.Skeletal radiology · 2025Review
- Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams.Life (Basel, Switzerland) · 2025Review
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- Fibrosis: cross-organ biology and pathways to development of innovative drugs.Nature reviews. Drug discovery · 2025Review
- Comment on: Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission.Rheumatology (Oxford, England) · 2025Article
- Molecular Imaging of Fibroblast Activation Protein in Response to Cardiac Injury Using [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.Current cardiology reports · 2025Review
- Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Targeting fibroblast activation protein in rheumatoid arthritis: from molecular imaging to precision therapeutics.Frontiers in immunology · 2025Review
- In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development.Circulation · 2024Review
- Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years.Rheumatology international · 2024Review
- Fibroblast activation protein inhibitor PET/CT as an emerging diagnostic modality in interstitial lung disease and other fibrotic conditions.Rheumatology and immunology research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
purposeMyocardial fibrosis (MF) is a factor of poor prognosis in systemic sclerosis (SSc). Direct in-vivo visualization of fibroblast activation as early readout of MF has not been feasible to date. Here, we characterize
methodsIn this proof-of-concept trial, six SSc patients with and eight without MF of the EUSTAR cohort Erlangen underwent [
results[
conclusionsWe present first in-human evidence that [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.